All News

2 June 2011

Lpath’s Anti-LPA Antibody, Lpathomab, Demonstrates Promising Data in Several Animal Models of DiseaseAntibodies

2 June 2011

ImmunoCellular Therapeutics and BioWa Announce License for the Research and Development of Therapeutic Antibodies in CancerAntibodies

2 June 2011

Morphotek, Inc. Announces Initiation of MORAb-004 Phase II Study in MelanomaAntibodies

2 June 2011

Bristol-Myers Squibb and Roche Enter into a Clinical Collaboration Agreement to Conduct Combination Studies with YERVOY (ipilimumab) and VemurafenibAntibodies

2 June 2011

AVEO’s Ficlatuzumab in Combination with Gefinitib Well Tolerated in Patients with Non-Small Cell Lung Cancer; Phase 1b Data Presented at ASCOAntibodies

1 June 2011

AVEO Pharmaceuticals Enters into Worldwide License Agreement with Centocor Ortho Biotech to Develop and Commercialize RON-Targeted AntibodiesAntibodies

1 June 2011

FDA Grants Priority Review for Alexion’s sBLA for Soliris (eculizumab) as a Treatment for Patients with Atypical Hemolytic Uremic Syndrome (aHUS)Antibodies

31 May 2011

YM BioSciences Provides Update on the Development Program for NimotuzumabAntibodies

30 May 2011

Thallion Announces First Patient Enrolled In High Dose Cohort of Phase II SHIGATEC TrialAntibodies

27 May 2011

RoACTEMRA could change the current standard of treatment for people living with rheumatoid arthritisAntibodies

26 May 2011

New data for Cimzia (certolizumab pegol) showed a rapid clinical response across a broad population of rheumatoid arthritis (RA) patientsAntibodies

25 May 2011

Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid ArthritisAntibodies

25 May 2011

UCB to conduct first anti-TNF head-to-head study between Cimzia (certolizumab pegol) and Humira (adalimumab)Antibodies

25 May 2011

Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. SteroidAntibodies

25 May 2011

Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel (etanercept) for Patients with Chronic Inflammatory ConditionsAntibodies

25 May 2011

Ablynx to Present Clinical Data on Its Anti-RANKL Nanobody at the Annual European Congress of RheumatologyAntibodies

25 May 2011

New Four Year STELARA Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque PsoriasisAntibodies

25 May 2011

Peregrine Announces Initiation of Phase I/II Prostate Cancer Investigator-Sponsored Trial (IST)Antibodies

24 May 2011

AstraZeneca signs agreement in Japan with Daiichi Sankyo to co-promote denosumab for cancerAntibodies

24 May 2011

RoActemra offers a new option for children living with a rare and severe form of arthritisAntibodies

23 May 2011

FDA Schedules Advisory Committee Meeting to Discuss BLA for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular DegenerationAntibodies

23 May 2011

Altor BioScience Awarded $3 MM SBIR Phase II Competing Renewal Grant by NHBLI to Complete a Second Phase 2 ALI/ARDS Clinical Trial for its Antibody-based Tissue Factor Antagonist, ALT-836Antibodies

20 May 2011

Amgen Receives CHMP Positive Opinion for XGEVA (Denosumab) in the European UnionAntibodies

20 May 2011

GlaxoSmithKline and Human Genome Sciences Receive Positive Opinion in Europe from the CHMP for BENLYSTA (Belimumab)Antibodies

19 May 2011

Lilly Presents Data on Cixutumumab in Five Subtypes of SarcomaAntibodies

18 May 2011

Roche to present significant progress in advanced skin, lung and ovarian cancers at ASCOAntibodies

18 May 2011

Phase 3 Data Demonstrate XGEVA(TM) (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate CancerAntibodies

18 May 2011

Biothera Initiates Dosing in a Phase III Trial in Colorectal Cancer PatientsAntibodies

17 May 2011

Pfizer’s Anti-TNF-Alpha Nanobody (ATN-103) Successfully Completes a Phase II Study and Demonstrates Clinical Proof-of-Concept (POC) in Patients With RAAntibodies

17 May 2011

Teva and CureTech Announce Positive Phase II Data from CT-011, an Investigational Antibody in Diffuse Large B Cell LymphomaAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

CD73 Inhibitor Pipeline Review

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Bispecific Antibodies for Immuno-Oncology & Other Diseases

Report Package: Claudin 18.2-Targeted Immunotherapeutics

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review

Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review

PSMA-Targeted Therapy Pipeline Review

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

5T4-Targeted Immunotherapy Candidates Pipeline Review